Tuesday, November 10, 2020

MissionIRNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Completion of Strategic Merger

 180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the successful closing of its transaction with KBL Merger Corp IV. Prior to the merger’s closing, KBL Merger Corp. changed its name to 180 Life Sciences Corp., and 180 Life Sciences Corp. changed its name to 180 Life Corp., which now operates as a wholly owned subsidiary of the company. As a result of the merger, the units and rights of KBL Merger Corp. ceased trading, and the shares of its common stock and warrants are now trading on the Nasdaq Capital Market under the ticker symbols “ATNF” and “ATNFW,” respectively. “We are excited to have completed the transaction resulting in 180 Life Sciences now being a public company. Not only does the company boast a tremendous pipeline of innovative therapies that use anti-TNF to treat inflammatory diseases, it also boasts an unparalleled team of pioneering and world-renowned scientists leading the charge – namely, Prof. Sir Marc Feldmann and Prof. Lawrence Steinman,” said Dr. James Woody, who leads 180 Life Sciences. “I look forward to working with them to discover new therapies to address inflammatory diseases, as well as building value for our shareholders.”

To view the full press release, visit https://ibn.fm/Mnvvq

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF, with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html